NM_001165963.4(SCN1A):c.5317T>C (p.Ser1773Pro)

Base Editing (BE4max) via AAV9 delivery is a rationale-driven therapeutic strategy for Dravet syndrome (SCN1A-related developmental and epileptic encephalopathy) targeting the SCN1A c.5317T>C (p.Ser1773Pro) variant (Pathogenic, missense variant, non-coding transcript variant). The editing system (BE4max (cytosine base editor)) converts the pathogenic C to T (or G to A on the target strand), restoring the wild-type codon. Target tissue: CNS. Therapeutic goal: Upregulate or correct SCN1A in inhibitory interneurons at the endogenous SCN1A locus to restore NaV1.1 function, reduce seizures, and prevent developmental deterioration in Dravet syndrome.. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity High (AAV pre-existing immunity).

1. Molecular basis: SCN1A NM_001165963.4(SCN1A):c.5317T>C (p.Ser1773Pro) is classified as Pathogenic (ClinVar variation ID 2817041). Molecular consequence: missense variant, non-coding transcript variant. Protein change: S1745P, S1744P, S1762P, S1773P, S1761P, S959P. 2. Epidemiology: Dravet syndrome is a rare, severe developmental and epileptic encephalopathy with onset in the first year of life, most often due to de novo heterozygous loss-of-function variants in SCN1A. Population-based data from the United States indicate that SCN1A-positive Dravet syndrome is more common than 3. Standard of care: Standard management relies on chronic antiseizure pharmacotherapy and nonpharmacologic measures rather than etiologic cure. Traditional first-line agents include valproate and clobazam, often combined with stiripentol; topiramate and bromide are also used. Ketogenic diet and vagus nerve stimulation 4. Pipeline: Beyond symptomatic antiseizure medications, multiple gene-targeted and disease-modifying strategies are in preclinical or early clinical development. Antisense oligonucleotides (e.g., STK-001) designed to upregulate SCN1A via splicing modulation have shown robust seizure and survival benefits in Dra 5. CBE clinical validation: BE4max (Koblan et al. 2018) is the gold-standard cytosine base editor. Multiple CBE programs are in clinical development for liver and hematologic targets.

1. No published data specifically correcting SCN1A c.5317T>C (p.Ser1773Pro) with Base Editing (BE4max); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 4. Delivery to CNS tissue remains a major translational bottleneck. Current vectors have limited transduction efficiency in these compartments. 4. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.